BackAN2 Therapeutics Overview

AN2 Therapeutics Research & Development

Research & Development expenses for ANTX.

Quarterly R&D Expenses

$6.74M
12.31% YoY

As of Mar 31, 2026

Annual R&D Expenses (TTM)

$23.82M
28.94% YoY

Trailing 12 months ending Mar 31, 2026

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)